Long-Term Efficacy, Predictors of Response, and Safety of Abrocitinib in Atopic Dermatitis: A Prospective Real-World Study

Description

In this dataset, we have provided supplementary information for the study titled "Long-Term Efficacy, Predictors of Response, and Safety of Abrocitinib in Atopic Dermatitis: A Prospective Real-World Study." The supplementary materials include supplementary document, figures and tables. A detailed description is provided below: Supplementary Methods: Provides additional methodological details on the Treatment, Outcome measure, and Serum biomarker profiles upon abrocitinib treatment. Supplementary Figure Legend S1-3. Supplementary Figure 1. Dynamic changes in EASI scores of different body sites during abrocitinib treatment. Supplementary Figure 2. Changes in blood eosinophil counts during abrocitinib treatment. Supplementary Figure 3. Cumulative incidence of abrocitinib discontinuation stratified by reason for treatment discontinuation. Supplementary Table S1-11: Table S1. Baseline demographic and clinical characteristics of AD patients; Table S2. Rate of changes in EASI scores stratified by different body sites; Table S3. Clinical factors stratified by patient-reported reflare episodes; Table S4. Clinical factors stratified by clinician-assessed reflare episodes; Table S5. Clinical factors stratified by successful versus unsuccessful dose reduction; Table S6. Overall and subgroup drug survival rates of abrocitinib; Table S7. Baseline predictors of treatment discontinuation; Table S8. Reasons for treatment discontinuation; Table S9. Adverse events during abrocitinib treatment; Table S10. Adverse events with abrocitinib after week 12, stratified by age group (<60 vs ≥60 years); Table S11. Baseline cytokine and chemokine levels in early responders and delayed responders.

Institutions

• Huashan Hospital Fudan University

  Shanghai, Shanghai

Categories

Licence